Basel, Switzerland, 22 October 2009 - Evolva SA, a Swiss headquartered international biotech company today announced a CHF 28 million first closing of its Series B financing round. The Series B financing is led by current investor Aravis and new investors Auriga Partners, Vinci Capital - Renaissance PME and Wellington Partners. BioMedInvest and an undisclosed private investor participated as co-investors in the first closing, as well as Evolva's existing investors Astellas Venture, Dansk Innovation, Novartis Bioventures and Sunstone Capital.
Evolva SA develops synthetic biopharmaceutical products. The Company produces a proprietary technology platform that uses synthetic biology to create small molecule drugs along with pipelines of compounds that addresses unmet medical needs, such as kidney and cardiovascular disease and influenza.
Market Data 
Markets 
AI
